Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUNIPER: Abemaciclib vs erlotinib in KRAS-mutant stage IV NSCLC after platinum therapy
jRCT2080222632Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of abemaciclib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Started Oct 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222632.